Overview
EndeavorRx, also marketed under the name Project: EVO, is a prescription digital therapeutic video game designed to improve attention function in children diagnosed with attention‑deficit/hyperactivity disorder (ADHD). Developed by Akili Interactive Labs, it is classified as a medical device (Class II) by the U.S. Food and Drug Administration (FDA).
Regulatory Status
- FDA clearance: June 2020. EndeavorRx received the first FDA clearance for a video game intended to treat a medical condition, specifically pediatric ADHD.
- Prescription requirement: The product must be prescribed by a qualified healthcare professional. It is indicated for children aged 8–12 years with ADHD.
Mechanism of Action
EndeavorRx is a 3‑dimensional, fast‑paced video game that presents a series of tasks requiring sustained attention, working memory, and inhibitory control. The game dynamically adjusts difficulty based on the player’s performance, aiming to train neural pathways associated with attentional control.
Clinical Evidence
- Pivotal trial (2020): A randomized, controlled, double‑blind study involving 151 participants (ages 8–12) demonstrated statistically significant improvements in objective measures of attention (as assessed by the Test of Variables of Attention, TOVA) after 28 days of gameplay (five 25‑minute sessions per week).
- Safety profile: The trial reported no serious adverse events. Commonly reported mild side effects included eye strain and fatigue.
Usage Guidelines
- Dosage: Recommended regimen is 25 minutes per session, five sessions per week, for a minimum of four weeks.
- Monitoring: Physicians are advised to monitor attention outcomes and any potential side effects throughout the treatment period.
Reception and Impact
EndeavorRx is recognized as the first FDA‑cleared prescription video game, marking a milestone in digital therapeutics. It has been cited in discussions about non‑pharmacologic interventions for ADHD and the broader integration of interactive technology into clinical practice. Adoption rates and long‑term efficacy data continue to be evaluated in post‑market studies.
Limitations
- The therapeutic effect is specific to attentional measures and does not address hyperactivity or impulsivity directly.
- Long‑term outcomes beyond the initial treatment window remain under investigation.
Related Developments
Akili Interactive has pursued additional FDA clearances for other digital therapeutic indications, leveraging the regulatory framework established with EndeavorRx.
